Karyopharm Therapeutics (KPTI) Equity Average (2013 - 2025)

Karyopharm Therapeutics has reported Equity Average for 13 years, with the latest figure at -$281.1 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 62.64% year-over-year to -$281.1 million; the trailing twelve-month figure through Dec 2025 stood at -$281.1 million (down 62.64% YoY), and the FY2025 full-year result was -$239.5 million, down 48.64% from the prior year.
• Equity Average for Q4 2025 stood at -$281.1 million, down from -$254.1 million in the prior quarter.
• The five-year high for Equity Average was $5.5 million in Q1 2021, with the low at -$281.1 million in Q4 2025.
• Historically, Equity Average has averaged -$126.0 million across 5 years, with a median of -$111.4 million in 2021.
• Annual changes were most pronounced in 2022 — Equity Average slumped 1592.32% — and 2023, when it surged 62.01%.
• Karyopharm Therapeutics' Equity Average stood at -$102.8 million in 2021, then gained by 23.69% to -$78.5 million in 2022, then plunged by 50.76% to -$118.3 million in 2023, then plunged by 46.1% to -$172.8 million in 2024, then sank by 62.64% to -$281.1 million in 2025.
• The last three Equity Average figures came in at -$281.1 million (Q4 2025), -$254.1 million (Q3 2025), and -$222.4 million (Q2 2025), per Business Quant data.